Editorial - Archives of Pharmacology and Therapeutics (2021) Volume 3, Issue 1
COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer
Daniel A. King1, Jeffrey Chi2, Shreya Prasad Goyal2, M. Wasif Saif2*
Stanford University, Stanford, CA, USA
Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY, USA
- *Corresponding Author:
- M. Wasif Saif
Received date: February 17, 2021; Accepted date: March 01, 2021
Citation: King DA, Chi J, Goyal SP, Saif MW. COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer. Arch Pharmacol Ther. 2021; 3(1):5-9.
Copyright: © 2021 King DA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
COVID-19, Cancer patients, Immunosuppressed,
Since the declaration of COVID-19 as a pandemic in March 2020 , there have been more than 100 million reported cases of COVID-19 worldwide and more than 2.1 million deaths . The purpose of this editorial is to review recent updates regarding COVID-19 disease and SARS-CoV-2 vaccination in cancer patients.
Several studies have shown that cancer patients infected with COVID-19 disease have high rates of morbidity and mortality, and that a substantial portion of deaths in cancer patients are attributable to COVID-19 infection. As examples, a meta-analysis that pooled 52 studies of 18,650 cancer patients showed a case-fatality rate of 25.6% . In a recent report comparing 41 and 35 cancer patients with and without COVID-19, respectively, the 30-day mortality of cancer patients with COVID-19 was 22%, compared to 0% in patients without COVID-19. A prospective cohort study estimated that greater than 90% of deaths in cancer patients with COVID-19 are attributable to COVID-19 . Cancer patients are about twice as likely to contract infection with SARS-CoV-2 , the virus causing
Several factors underlie the risks of cancer patients to become infected with SARS-CoV-2 and their propensity toward developing COVID-19 complications. Patients with cancer have weakened immune systems leading to vulnerability to infection. In some cases, this is due to immune dysregulation intrinsic to the cancer, especially apparent in hematologic malignancies [4,6,7], but more broadly, immunosuppression is induced by cancerdirected therapy, by regimens that are cytotoxic to the immune system, either directly, such as with bone marrow transplantion , or indirectly, by cytotoxic chemotherapy
. Whereas patients affected by COVID-19 without
cancer can clear SARS-CoV-2 viremia within 1-2 weeks,
clearance is delayed for patients with solid tumors (29
days) , with hematologic malignancies (55 days)
, and with hematologic malignancies undergoing
stem-cell transplantation (longer than 2 months) .
Lymphopenia, which is predictive for severe COVID-19
disease, persists after SARS-CoV-2 infection, especially in
patients with hematologic malignancies . Separately,
lung cancer is associated with severe COVID-19 disease
and portends poorer outcome in the context of COVID-19,
which is likely related to prior smoking history, leading to
impaired pulmonary function and poor respiratory reserve
. Among patients with solid tumors, the diagnosis of
cancer less than 5 years is associated with increased risk,
especially in the first year, but the risk drops to baseline if
the diagnosis is greater than 5 years . Lastly, patients
with cancer have a generally poorer substrate, with a
constitution often already weakened by their cancer, and
cancer patients are generally older, tend to be in overall
poorer health and have comorbid conditions.
Vaccine development against SARS-CoV-2 manifested with extraordinary pace. The virus emerged as early as November 2019 [13,14] and the full viral sequence, a requisite for mRNA vaccine development , was published by January 2020 . By the second half of 2020, at which point more than 120 candidate SARS-CoV2 vaccines were in development , mRNA vaccines showed excellent antibody responses without safety concerns in non-human primates , and in phase 1 studies [19,20], prompting their further developing into phase 3 trials. In December 2020, phase 3 COVID-19 trials were reported by Moderna  (mRNA-1273) and by a partnership
between Pfizer and BioNTech  (BNT162b2). These
trials had similar design, both randomizing participants to
vaccine or placebo and compared the rate of symptomatic
COVID-positive infections following completion of twodose
vaccination. In aggregate, these trials administered
vaccines to more than 30 thousand participants; serious
adverse events were rare and the vaccines were remarkably
effective, with efficacies of 94.1% (Moderna ) and
94.6% (Pfizer ). Based on these randomized phase 3
data, the FDA issued emergency use authorization to both
vaccines in December 2020, permitting administration
to people at least 16 years (Pfizer-BioNTech) or 18 years
(Moderna) of age. The mRNA vaccines require two
doses and require freezer storage, factors which hinder
distribution and full vaccination, especially in developing
countries. Phase 3 trials are underway for at least 8
additional SARS-CoV-2 vaccines , including vaccines
not requiring freezer storage. Interim analyses released
in press releases by Novavax of its two-dose spikeprotein
vaccine (NVX-CoV2373) , and by Johnson &
Johnson, and its subsidary, Janssen, of its single- injection
refrigerator-storage adenovirus viral vector vaccine
(Ad.26.COV2.S) , are highly encouraging and may
lead to future emergency use authorization. Similarly,
the Chinese CoronaVac inactivated viral particle vaccine
and the Russian Sputnik V adenovirus viral vector vaccine
are of note because they were the first to be developed
but trials demonstrating their effectiveness have also
not yet undergone peer review as of January 2021 .
Distribution of COVID-19 vaccines is underway, with more
than 70 million doses delivered among 57 countries as of
late January 2021 .
The CDC developed a framework consisting of four ethical principles to guide distribution of vaccines , to ensure that allocation maximizes protection of those at risk of infection and at risk of morbidity or mortality to the virus . Their guidelines call for staggered roll-out by phases, with highest priority, phase 1a, for health care personnel and long-term care facility residents, and phase 1b for frontline essential workers or patients at least 75 years old. Those not otherwise qualifying for the 75 million people among phase 1a or 1b, but who have cancer or other high-risk medical conditions, are included in phase 1c of vaccine distribution.
Data regarding safety and efficacy of COVID-19 vaccination in cancer patients is limited. Both phase 3 COVID-19 trials described above excluded patients with a known history of immunosuppressive therapy. The Pfizer study  explicitly excluded patients with a diagnosis of an immunocompromising condition. Only 3.7% of patients receiving the vaccine had a diagnosis of cancer, presumably not receiving active treatment, and while the adverse events experienced in this sub-group was not reported, the overall rate serious adverse events in the unselected study population was very low (<1%) . The
number of subjects with cancer was not reported on the
Moderna trial. Taken together, limited empirical data exist
for predicting safety in the cancer population. However,
as mRNA vaccines do not deliver live virus, the National
Center for Immunization and Respiratory Diseases advises
that while the risks to immunocompromised patients are
unknown, the vaccine is unlikely to pose a risk to safety
. Regarding efficacy, data suggest that the vaccination
is likely to be effective even in patients undergoing cancer
treatment. For example, it appears that most patients with
solid malignancies affected by COVID-19, even with severe
COVID-19 disease, are able to mount an immune response
and produce antibodies against SARS-COV-2, although
responses may be blunted in patients with hematologic
For oncologists, the main question at hand is whether vaccination of patients undergoing active treatment for cancer merit vaccination for COVID-19. Emerging guidelines argue that the benefits generally outweigh the harms of vaccination. As nicely articulated by Dr. Steve Pergram, Co-Leader of the NCCN COVID-19 Vaccination Advisory Committee, “Cancer patients are not expected to be at risk for complications of the vaccine. They are at risk for acquisition and complications of the virus” .
The American Association of Cancer Research’s COVID-19 and Cancer Task Force recommend priority COVID-19 vaccination for cancer patients, especially those with hematologic malignancies, given an increased rate of severe COVID infection and death . The National Comprehensive Cancer Network (NCCN), noting unknown vaccine efficacy in the setting of cancer care and a weakened immune system but acknowledging high-risk of COVID-19 associated complications, recommends that patients with cancer should be prioritized for vaccination and immunized when a vaccine is available to them (Table 1) . The European Society for Medical Oncology (ESMO) recommends that immunocompromised patients with cancer have an increased risk of severe COVID-19 disease and should be vaccinated against the SARS-CoV-2 virus with high priority . If possible, vaccination should be administered before the initiation of chemotherapy , but if it has already been initiated there is no clear guidance on timing around chemotherapy infusions [34,35]. It is possible that multiple doses (beyond the standard vaccination dosage guidelines) may be required in order to reach adequate seroconversion and seroprotective rates in cancer patients on chemotherapy .
|Hematopoietic Cell Transplantation (HCT)/ Cellular Therapy|| |
|Allogeneic Transplantation Autologous Transplantation Cellular therapy (e.g., CAR-T cell)|| At least 3 months post- HCT/ cellular therapy|
|Hematologic malignancies|| |
|Receiving intensive cytotoxic chemotherapy (e.g. cytarabine/ anthracycline-based induction regimens for AML)||Delay until absolute neutrophil count (ANC) recovery|
|Marrow failure from disease and/or therapy expected to have limited or no recovery|| When vaccine available|
|Long-term maintenance therapy (e.g., targeted agents for chronic lymphocytic leukemia or myeloproliferative neoplasms)|| When vaccine available|
|Solid tumor malignancies|| |
|Receiving cytotoxic chemotherapy||When vaccine available|
|Targeted therapy||When vaccine available|
|Checkpoint inhibitors and other immunotherapy||When vaccine available|
|Radiation||When vaccine available|
|Major surgery||Separate date of surgery from vaccination by at least a few days|
|Caregivers and Household/Close Contacts (= 16 years of age)|| |
|Any time eligible to receive the vaccine|| |
†COVID-19 vaccines should be prioritized over other needed vaccines, as data on dual vaccination is not available to date. 14 daysrecommended between COVID-19 vaccines and other approved vaccines.
Table 1: COVID-19 Vaccination Recommendations for Cancer Patients. Adapted from NCCN guidelines .
Lessons from influenza vaccination provide an analogous vaccination model. Data suggest that cancer patients are able to mount an immune response to influenza [34,36], and on the basis of observational data, influenza vaccination is associated with lower mortality and absence of safety concerns [34,37]. On this basis, patients with active malignancies are recommended to receive the
influenza vaccine , and may well be appropriate
COVID-19 vaccine candidates.
Ultimately, cancer patients will need to be closely monitored after COVID-19 vaccination to assess for any adverse events, both related to COVID-19 (infection, severity and/or mortality) and cancer (complications, mortality) . In time, further data are likely to additionally refine guidelines related to COVID-19 vaccination in the cancer population.
- Ghebreyesus T. WHO Director-General’s opening
remarks at the media briefing on COVID-19. Published
2020. Accessed January 17, 2021. https://www.who.int/
- Worldometers.info. Worldometer COVID-19
Data. Published 2021. Accessed January 27, 2021.
- Saini KS, Tagliamento M, Lambertini M, McNally
R, Romano M, Leone M, et al. Mortality in patients
with cancer and coronavirus disease 2019: A systematic
review and pooled analysis of 52 studies. Eur J Cancer.
- Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V,
Campton NA, et al. COVID-19 mortality in patients with
cancer on chemotherapy or other anticancer treatments:
a prospective cohort study. Lancet (London, England).
- Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2
Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020;6(7):1108-
- Abdul-Jawad S, Baù L, Alaguthurai T, Del Molino
Del Barrio I, Laing AG, Hayday TS, et al. Acute Immune
Signatures and Their Legacies in Severe Acute Respiratory
Syndrome Coronavirus-2 Infected Cancer Patients.
Cancer Cell. 2021 Feb 8;39(2):257-275.e6.
- Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti
T, Deaglio S. Immune Response Dysfunction in
Chronic Lymphocytic Leukemia: Dissecting Molecular
Mechanisms and Microenvironmental Conditions. Int J
Mol Sci. 2020;21(5).
- Ljungman P, Mikulska M, de la Camara R, Basak
GW, Chabannon C, Corbacioglu S, et al. The challenge of
COVID-19 and hematopoietic cell transplantation; EBMT
recommendations for management of hematopoietic
cell transplant recipients, their donors, and patients
undergoing CAR T-cell therapy. Bone Marrow Transplant.
- Rüthrich MM, Giessen-Jung C, Borgmann S, Classen
AY, Dolff S, Grüner B, et al. COVID-19 in cancer patients:
clinical characteristics and outcome-an analysis of the
LEOSS registry. Ann Hematol. 2021;100(2):383-393.
- Aydillo T, Gonzalez-Reiche AS, Aslam S, van de
Guchte A, Khan Z, Obla A, et al. Shedding of Viable SARSCoV-
2 after Immunosuppressive Therapy for Cancer. N
Engl J Med. 2020;383(26):2586-2588.
- Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos
D, Bandlamudi C, et al. COVID-19 in patients with
lung cancer. Ann Oncol Off J Eur Soc Med Oncol.
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon
S, Bates C, Morton CE, et al. Factors associated with
COVID-19-related death using OpenSAFELY. Nature.
- Josephine Ma. Coronavirus: China’s first confirmed Covid-19 case traced back to November 17. Published 2020. https://www.scmp.com/news/china/society/ article/3074991/coronavirus-chinas-first-confirmedcovid- 19-case-traced-back
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et
al. A Novel Coronavirus from Patients with Pneumonia in
China, 2019. N Engl J Med. 2020;382(8):727-733.
- Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA
vaccines-a new era in vaccinology. Nat Rev Drug Discov.
- Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et
al. A new coronavirus associated with human respiratory
disease in China. Nature. 2020;579(7798):265-269.
- WHO. Draft landscape of COVID-19 candidate
vaccines. Published 2020. Accessed July 14, 2020.
- Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the
mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman
Primates. N Engl J Med. 2020;383(16):1544-1555.
- Jackson LA, Anderson EJ, Rouphael NG, Roberts
PC, Makhene M, Coler RN, et al. An mRNA Vaccine
against SARS-CoV-2 — Preliminary Report. N Engl J
- Mulligan MJ, Lyke KE, Kitchin N, Absalon J,
Gurtman A, Lockhart S, et al. Phase I/II study of
COVID-19 RNA vaccine BNT162b1 in adults. Nature.
- Baden LR, El Sahly HM, Essink B, Kotloff K, Frey
S, Novak R, et al. Efficacy and Safety of the mRNA-1273
SARS-CoV-2 Vaccine. N Engl J Med. Published online
- Polack FP, Thomas SJ, Kitchin N, Absalon J,
Gurtman A, Lockhart S, et al. Safety and Efficacy of the
BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med.
- Poland GA, Ovsyannikova IG, Kennedy RB. SARSCoV-
2 immunity: review and applications to phase
3 vaccine candidates. Lancet (London, England).
- Novavax I. Novavax COVID-19 Vaccine Demonstrates
89.3% Efficacy in UK Phase 3 Trial. Published 2021.
Accessed January 31, 2021. https://ir.novavax.com/
- Johnson J&. Johnson & Johnson Announces Single-
Shot Janssen COVID-19 Vaccine Candidate Met Primary
Endpoints in Interim Analysis of its Phase 3 ENSEMBLE
Trial. Published 2021. Accessed January 31, 2021.
- Randall T. More Than 71.3 Million Shots Given:
Covid-19 Tracker. Published 2021. Accessed January
27, 2021. https://www.bloomberg.com/graphics/covidvaccine-
- McClung N, Chamberland M, Kinlaw K, Bowen
Matthew D, Wallace M, Bell BP, et al. The Advisory
Committee on Immunization Practices’ Ethical Principles
for Allocating Initial Supplies of COVID-19 Vaccine -
United States, 2020. MMWR Morb Mortal Wkly Rep.
- Dooling K, Marin M, Wallace M, McClung
N, Chamberland M, Lee GM, et al. The Advisory Committee on Immunization Practices’ Updated Interim
Recommendation for Allocation of COVID-19 Vaccine
— United States, December 2020. MMWR Morb Mortal
Wkly Rep. 2021;69(5152):1657-1660.
- Diseases NC for I and R. Interim Clinical
Considerations for Use of mRNA COVID-19 Vaccines
Currently Authorized in the United States. Published
2021. Accessed January 27, 2021. https://www.cdc.
- Mapes D. Cancer patients and the COVID-19
vaccines. FRED HUTCH NEWS SERVICE. Published
2021. Accessed January 24, 2021. https://www.
- Ribas A, Sengupta R, Locke T, Zaidi SK, Campbell
KM, Carethers JM, et al. Priority COVID-19 Vaccination
for Patients with Cancer while Vaccine Supply Is Limited.
Cancer Discov. 2021;11(2):233-236.
- NCCN. Preliminary recommendations of the NCCN
COVID-19 vaccination advisory committee, version 1.0.
Preliminary recommendations of the NCCN COVID-19
vaccination advisory committee, version 1.0. Accessed
January 22, 2021. https://www.nccn.org/covid-19/pdf/
- European Society for Medical Oncology (ESMO).
Esmo Statements for Vaccination Against Covid-19 in
Patients With Cancer. ESMO. Published 2020. Accessed
January 26, 2021. https://www.esmo.org/covid-19-andcancer/
- Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery
R, Tomblyn M, et al. 2013 IDSA clinical practice guideline
for vaccination of the immunocompromised host. Clin
Infect Dis an Off Publ Infect Dis Soc Am. 2014;58(3):e44-
- Rousseau B, Loulergue P, Mir O, Krivine A, Kotti S,
Viel E, et al. Immunogenicity and safety of the influenza
A H1N1v 2009 vaccine in cancer patients treated with
cytotoxic chemotherapy and/or targeted therapy: the
VACANCE study. Ann Oncol Off J Eur Soc Med Oncol.
- Ward EM, Flowers CR, Gansler T, Omer SB,
Bednarczyk RA. The importance of immunization
in cancer prevention, treatment, and survivorship.
CA Cancer J Clin. 2017;67(5):398-410. doi:10.3322/
- Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici
Trestioreanu A, Leibovici L, Paul M. Influenza vaccines
in immunosuppressed adults with cancer. Cochrane
database Syst Rev. 2018;2(2):CD008983.